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In a result that will fundamentally change approaches to HIV prevention in Africa, an international 
study has demonstrated that individuals at high risk for HIV infection who took a daily tablet 
containing an HIV medication – either the antiretroviral medication tenofovir (TDF) or tenofovir in 
combination with emtricitabine (FTC/TDF) – experienced significantly fewer HIV infections than 
those who received a placebo pill. These findings are clear evidence that this new HIV prevention 
strategy, called pre-exposure prophylaxis (or PrEP), substantially reduces HIV infection risk. 
The study was led by University of Washington’s Dr. Jared Baeten and Dr Connie Celum and 
Vaccine and Infectious Disease Division’s Dr. Deborah Donnell, along with collaborators in the 
Partners Pre-exposure Prophylaxis (PrEP) Study and enrolled 4758 heterosexual serodiscordant 
couples from nine sites in Kenya and Uganda. Seronegative partners were assigned to one of three 
study groups: TDF, TDF-FTC, or placebo.  The seropositive partner, at study enrollment, was not 
eligible for antiretroviral therapy according to national guidelines. Couples were in the study for up to 
three years; seronegative participants had monthly visits for HIV-1 testing, dispensation of study 
medication, and other HIV-1 prevention services and counseling. 
During the study, a total of 82 HIV-1 infections occurred in seronegative participants: 17 in the TDF 
group (incidence, 0.65 per 100 person-years), 13 in the TDF-FTC group (incidence, 0.50 per 100 
person-years), and 52 in the placebo group (incidence, 1.99 per 100 person-years). This represents 
a relative reduction in risk of HIV-1 infection of 67%  with TDF and 75% with FTC/TDF. The 
protective effects of the two preexposure prophylaxis treatments were not significantly different from 
each other, and both TDF and FTC/TDF significantly reduced HIV-1 incidence in both men and 
women. This study demonstrates that preexposure prophylaxis could be an effective HIV-1 
prevention study for uninfected persons with partners who do not know their HIV status or are known 
to be infected, but have not yet become eligible for antiretroviral therapy. The researchers note that 
successful prevention of HIV-1 on a worldwide scale will likely need to incorporate multiple 
strategies, both medical and behavioral, to achieve maximum benefit and stem the global HIV-
epidemic. 
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Kaplan-Meier estimates of seropositivity in the modified intention-to-treat 
analysis, according to study treatment. Cumulative probability of HIV-1 infection 
is shown on the y-axis, and months since randomization is shown on the x-axis. 
 
